When it comes to wounds that won't heal, medicine has long faced an expensive and frustrating problem. Chronic and 'untreatable' wounds, often seen in diabetics, post-surgical patients, and those battling infections, cost healthcare systems billions annually. With the global wound care market projected to exceed $30 billion in the next few years, the need for more effective solutions is only growing. Even the most advanced pharmaceutical wound treatments hover around 50% efficacy, leaving far too many patients without real solutions.
For Jasen Petersen, co-founder and CEO of Ionic Alliance Group, Inc. (IAG), that statistic is unacceptable. Petersen has developed Ion Biotechnology Aqueous Ligands (IBAL), a new class of therapeutic technology that he describes as a microimmune restorative. The origins of this technology trace back thousands of years to an indigenous tradition of applying mineral-rich compounds to treat infected wounds, a practice now refined into a precise, pharmaceutical-grade ion delivery system.
